Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access bardoxolone methyl for pulmonary hypertension
NL-OMON49960Phase 3Active, not recruiting
- Sponsor
- Reata Pharmaceuticals
- Start
- Aug 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bardoxolone methyl in pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH), sponsored by Reata Pharmaceuticals. Primary endpoints: Safety and tolerability, Change from baseline in physical examination findings and 4 more. Started Aug 2017; status: active, not recruiting.
02
Drugs
bardoxolone methyl
03
Conditions
pulmonary hypertension (PH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON49960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49960.